TRASTUZUMAB VEDOTIN

UNII:	W95G28K44S
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	TRASTUZUMAB VEDOTIN
GSRS Full Record:	W95G28K44S i

2740607-04-7
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450))(121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (86.3%) - IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, glycoform alfa; conjugated, on an average of 3-4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valylcitrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker
Immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody; conjugated to auristatin E
MRG 002 [WHO-DD]
MRG-002
MRG002
TRASTUZUMAB--VCMMAE CONJUGATE
Trastuzumab Vedotin
trastuzumab vedotin [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

TRASTUZUMAB VEDOTIN

Synonyms and Mappings

Resources